Crescent Biopharma (CBIO) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChart

Crescent Biopharma Revenue Highlights


00

Main Segment (Y)

Reportable Segment

Crescent Biopharma Revenue by Period


Crescent Biopharma Revenue by Year

DateRevenueChange
2025-12-31-100.00%
2024-12-31--100.00%
2023-12-31$10.00K-86.67%
2022-12-31$75.00K-93.53%
2021-12-31$1.16M-88.59%
2020-12-31$10.16M100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31--100.00%
2016-12-31$18.50K-99.91%
2015-12-31$20.07M33.56%
2014-12-31$15.03M276.37%
2013-12-31$3.99M-73.83%
2012-12-31$15.26M300.04%
2011-12-31$3.81M-

Crescent Biopharma generated - in revenue during NA 2025, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Crescent Biopharma Revenue by Quarter

DateRevenueChange
2026-03-31--100.00%
2025-12-31$10.84M-64.52%
2025-09-30$30.56M100.00%
2025-06-30-100.00%
2025-03-31-100.00%
2024-12-31-100.00%
2024-09-30-100.00%
2024-06-30-100.00%
2024-03-31--100.00%
2023-12-31$10.00K100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31--100.00%
2022-12-31$-75.00K100.00%
2022-09-30--100.00%
2022-06-30$75.00K100.00%
2022-03-31--100.00%
2021-12-31$17.63K-79.64%
2021-09-30$86.56K60857.75%
2021-06-30$142.00-99.99%
2021-03-31$1.06M547.77%
2020-12-31$162.94K-83.71%
2020-09-30$1.00M100.00%
2020-06-30--100.00%
2020-03-31$9.00M100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31--

Crescent Biopharma generated - in revenue during Q1 2026, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

Crescent Biopharma Revenue Breakdown


Crescent Biopharma Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24
Reportable Segment$10.84M-
Product-$105.80M

Crescent Biopharma's latest annual revenue breakdown by segment (product or service), as of Dec 25: Reportable Segment (100.00%).

Quarterly Revenue by Product

Product/ServiceMar 26Dec 25Sep 25Jun 25
Reportable Segment$1.04M$8.05M$2.79M-
Product--$30.60M$26.80M

Crescent Biopharma's latest quarterly revenue breakdown by segment (product or service), as of Mar 26: Reportable Segment (100.00%).

Crescent Biopharma Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
HRTXHeron Therapeutics$154.90M$34.71M
SGMOSangamo Therapeutics$57.80M$1.44M
IPHAInnate Pharma$51.90M$16.56M
CGENCompugen$33.46M$2.56M
OABIOmniAb$18.67M$14.43M
TNXPTonix Pharmaceuticals$13.11M$6.88M
IMDXInsight Molecular Diagnostics$4.05M$32.00K
HINDVyome$319.71K$31.59K
CCCCC4 Therapeutics--
CBIOCrescent Biopharma--

CBIO Revenue FAQ


What is Crescent Biopharma’s yearly revenue?

Crescent Biopharma's yearly revenue for 2025 was $0, representing an increase of 100.00% compared to 2024. The company's yearly revenue for 2024 was $0, representing a decrease of -100.00% compared to 2023. CBIO's yearly revenue for 2023 was $10K, representing a decrease of -86.67% compared to 2022.

What is Crescent Biopharma’s quarterly revenue?

Crescent Biopharma's quarterly revenue for Q1 2026 was $0, a -100.00% decrease from the previous quarter (Q4 2025), and a 0% increase year-over-year (Q1 2025). The company's quarterly revenue for Q4 2025 was $10.84M, a -64.52% decrease from the previous quarter (Q3 2025), and a 0% increase year-over-year (Q4 2024). CBIO's quarterly revenue for Q3 2025 was $30.56M, a 100.00% increase from the previous quarter (Q2 2025), and a 0% increase year-over-year (Q3 2024).

What is Crescent Biopharma’s revenue growth rate?

Crescent Biopharma's revenue growth rate for the last 3 years (2023-2025) was -100.00%, and for the last 5 years (2021-2025) was -100.00%.

What are Crescent Biopharma’s revenue streams?

Crescent Biopharma's revenue streams in c 25 are Reportable Segment

What is Crescent Biopharma’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Crescent Biopharma was Reportable Segment. This segment made a revenue of $10.84M, representing 100.00% of the company's total revenue.